Despite the high prevalence of KRAS mutations in pancreatic cancer, the ctDNA detection rates are 50–75% in metastatic patients with pancreatic cancer, which is lower than that in patients with breast or lung cancers, whose detection rate is usually less than 70–80% (30). This evidence concerns the gene KRAS and lung carcinoma.